ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...
Abbott Diabetes Care has alerted patients that the FreeStyle Libre 3 and Libre 3 Plus glucose sensors may provide incorrect low glucose readings. The FDA posted an Early Alert about the issue on ...
The Food and Drug Administration issued an “early alert” concerning FreeStyle Libre 3 and FreeStyle Libre Plus sensors used by people who have diabetes. The agency said Abbott Diabetes Care has sent a ...
Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that a number of them may be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results